Spontaneous healing of rectal penetration by SpaceOAR ® hydrogel insertion during permanent iodine-125 implant brachytherapy: A case report.

Spontaneous healing of rectal penetration by SpaceOAR® hydrogel insertion during permanent iodine-125 implant brachytherapy: A case report. Mol Clin Oncol. 2019 Dec;11(6):580-582 Authors: Iinuma K, Mizutani K, Kato T, Nakane K, Tanaka H, Nakano M, Matsuo M, Koie T Abstract Radiation therapy with permanent iodine-125 implant brachytherapy is well established for curable prostate cancer. To maximize the therapeutic potential of brachytherapy, delivered radiation doses have been increased accompanied by refined intraoperative procedures of radioactive seeds placement. However, dose escalation is a double-edged sword in prostate brachytherapy; it could induce rectal toxicity, yet is successful in curable treatment in prostate cancer. To reduce irradiation of the rectum, the SpaceOAR® system has been used to inject synthetic polyethylene glycol hydrogel between the prostate and the rectum. The present report describes a case of spontaneous healing of rectal penetration associated with SpaceOAR® hydrogel. PMID: 31692963 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research

Related Links:

Conclusions: Higher dose volumes for the bladder and rectum predicted for poorer PR-QOL. In contrast to prostate brachytherapy data, neither prostate volume nor urethral dosimetry at this dose schedule correlated with urinary symptoms.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
CONCLUSIONS: Higher dose volumes for the bladder and rectum predicted for poorer PR-QOL. In contrast to prostate brachytherapy data, neither prostate volume nor urethral dosimetry at this dose schedule correlated with urinary symptoms. PMID: 31584457 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Am J Clin Oncol Source Type: research
Radiation induced erectile dysfunction (RiED) remains a significant problem for patients undergoing radiation therapy (RT) for prostate cancer. SpaceOAR (Augmenix, Boston MA) hydrogel is placed in the rectoprostatic space to displace the prostate from the rectum and has demonstrated to reduce rectal toxicity. SpaceOAR hydrogel patients receiving EBRT were also more likely to preserve sexual function in a phase III trial. While the proposed mechanism of this improvement was via lower mean radiation doses to the penile bulb, both groups of patients received RT doses below the published dose-tolerances of this structure.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Authors: Trager M, Greenberger B, Harrison AS, Keller J, Den RB Abstract High-dose-rate (HDR) brachytherapy is an attractive option for patients receiving definitive radiation therapy for prostate cancer with decreased overall dose to the pelvis. However, ulcerative colitis increases rectal toxicity risk and may be a contraindication. A synthetic hydrogel, SpaceOAR (Augmentix Inc., Waltham, MA, USA), can facilitate the use of HDR brachytherapy for patients where rectal toxicity is a limiting factor. SpaceOAR gel (13.19 cc) was utilized in a monotherapy HDR prostate treatment with Ir-192 under transrectal ultrasound...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Authors: Chapman CH, Braunstein SE, Pouliot J, Noworolski SM, Weinberg V, Cunha A, Kurhanewicz J, Gottschalk AR, Roach MI, Hsu IC Abstract Purpose: Radiation dose escalation for prostate cancer improves biochemical control but is limited by toxicity. Magnetic resonance spectroscopic imaging (MRSI) can define dominant intraprostatic lesions (DIL). This phase I study evaluated dose escalation to MRSI-defined DIL using high-dose-rate (HDR) brachytherapy. Material and methods: Enrollment was closed early due to low accrual. Ten patients with prostate cancer (T2a-3b, Gleason 6-9, PSA
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
This study investigates rectal sparing achieved in high dose rate (HDR) prostate brachytherapy patients with hydrogel spacer implantation.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Salvage prostate permanent implant (sPPI) for locally recurrent prostate cancer after prostate dose-escalated radiotherapy or brachytherapy may harm the rectum.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
This study investigates rectal sparing achieved in high dose rate (HDR) prostate brachytherapy patients with hydrogel spacer implantation.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Abstract Radiation therapy represents an alternative treatment to radical prostatectomy in the management of clinically localized prostate cancer. Radiation-induced second neoplasms are defined by a latency period of at least 5 years, location within the field of radiation therapy, and a histology which differs from the primary tumor. Based on the data in the literature, there is a consistently increased risk of bladder cancer (HR: 1.67, 95% CI 1.55-1.80), rectal cancer (HR: 1.79, 95% CI 1.34-2.38), and colorectal cancer (HR: 1.79, 95% CI 1.34-23.8) following percutaneous radiation therapy. Fol...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
Augmenix said today it won a category 1 current procedural terminology reimbursement code from the American Medical Association for periprostatic implantation of biodegradable material, covering its flagship SpaceOAR device. The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said. The device is delivered through a small needle as a liquid, which then solidifies into a soft gel that expands the space between the prostate and rectum during radiotherapy. The substance then liquefies and is absorbed and cleared from the body in the patient&r...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Urology Augmenix Inc. Source Type: news
More News: Brachytherapy | Cancer | Cancer & Oncology | Colorectal Cancer | Iodine | Polyethylene Glycol | Prostate Cancer | Radiation Therapy | Toxicology